Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Thursday, October 16, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals announced promising preclinical data indicating that oral Mira-55 effectively normalized pain and significantly reduced inflammation, outperforming injected morphine. This development supports the company's plans for an Investigational New Drug (IND) application targeting chronic inflammatory pain. The findings bolster MIRA's competitive stance in the growing non-opioid pain management market.
Price reaction · baseline $1.32 (2025-10-15 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close
+36.4%
day 1
+22.7%
day 3
+9.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Oral Mira-55 fully normalized pain in preclinical studies.
  • Significantly reduced inflammation compared to injected morphine.
  • Supports MIRA's IND plans for chronic inflammatory pain.
  • Reinforces MIRA's position in a $70 billion non-opioid pain market.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA’s position in a $70 billion non-opioid pain market. MIAMI, FLORIDA / ACCESS Newswire / October 16, 2025 / MIRA Pharmaceuticals, Inc . (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, announced new preclinical data showing that oral Mira…
You can read the full content here

Frequently Asked Questions

What is oral Mira-55?

Oral Mira-55 is a novel therapy developed by MIRA Pharmaceuticals for pain management.

How does oral Mira-55 compare to morphine?

Oral Mira-55 has been shown to outperform injected morphine in normalizing pain and reducing inflammation.

What is the significance of the IND plans?

The IND plans aim to advance oral Mira-55 for treating chronic inflammatory pain.

What market is MIRA Pharmaceuticals targeting?

MIRA is targeting the $70 billion non-opioid pain management market.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals Mira-55 chronic pain non-opioid pain inflammation
Last updated: Oct 16, 2025

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →